C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia - Influence of antibiotic pre-treatment: Results from the German competence network CAPNETZ

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 1, 2009, Pages 159-162

  Krüger, Stefan ^a,g   Ewig, Santiago ^b,g   Kunde, Jan ^c   Hanschmann, Alexa ^c   Marre, Reinhard ^d   Suttorp, Norbert ^e   Welte, Tobias ^f,g   Becker, Markus ^g   Kuhnke, Antje ^g   Lode, Hartmut ^g   Schmidt Ioanas, Malina ^g   Suttorp, Barbara ^g   Bauer, Torsten ^g   Schlosser, Barbara ^g   Plets, Matthias ^g   Dalhoff, Klaus ^g   Pischke, Sven ^g   Schübel, Niels ^g   Huntemann, Ingrid ^g   Lorenz, Joachim ^g   Klante, Thomas ^g   Schaberg, Tom ^g   Voigt, Konstanze ^g   Schumann, Christian ^g   Jany, Berthold ^g   Ziegler, Uwe ^g   Illman, Torsten ^g   Wallner, Michael ^g   Weber, Michael ^g   von Baum, Heike ^g   Gonschior, Susanne ^g   Richter, Klaus ^g   more..

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Augusta Kranken Anstalt   (Germany)

^c BRAHMS AG   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g NONE

Author keywords

Antibiotics; Biomarkers; CAP

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COPEPTIN; PROCALCITONIN; PROVASOPRESSIN; UNCLASSIFIED DRUG; VASOPRESSIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GERMANY; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SCORING SYSTEM;

EID: 67249102755     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp148     Document Type: Article

References (10)

1. Welte T, Suttorp N, Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection 2004; 32: 234-8.
2. Almirall J, Bolibar I, Vidal J et al. Epidemiology of community-acquired pneumonia in adults: A population-based study. Eur Respir J 2000; 15: 757-63.
3. Krüger S, Papassotiriou J, Marre R et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia. Results from the German competence network CAPNETZ. Intensive Care Med 2007; 33: 2069-78.
4. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax 2003; 58 377-82.
5. Capelastegui A, Espana PP, Quintana JM et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006; 27: 151-7.
6. Bauer TT, Ewig S, Marre R et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260: 93-101.
7. Buising KL, Thursky KA, Black JF et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: Reconsidering what is meant by severe pneumonia. Thorax 2006; 61: 419-24.
8. Jochberger S, Morgenthaler NG, Mayr VD et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006; 91: 4281-6.
9. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
10. Mauch H, Marklein G, Kühnen E. Infektionen der tiefen Atemwege. In: Mauch H, Lütticken R, Gatermann S, eds. Qualitätsstandards in der Mikrobiologischen Diagnostik. München: Urban & Fischer, 1999.